Aldactone and Intervertebral disc space narrowing - a phase IV clinical study of FDA data

Summary:

Intervertebral disc space narrowing is reported as a side effect among people who take Aldactone (spironolactone), especially for people who are male, 60+ old, also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Intervertebral disc space narrowing when taking Aldactone. It is created by eHealthMe based on reports of 45,404 people who have side effects when taking Aldactone from the FDA, and is updated regularly.

What is Aldactone?

Aldactone has active ingredients of spironolactone. It is often used in acne. eHealthMe is studying from 46,063 Aldactone users. Check the latest studies of Aldactone.

What is Intervertebral disc space narrowing?

Intervertebral disc space narrowing (spinal disc space narrowing) is found to be associated with 452 drugs and 316 conditions by eHealthMe. Check the latest studies of Intervertebral disc space narrowing.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

45,404 people reported to have side effects when taking Aldactone.
Among them, 12 people (0.03%) have Intervertebral disc space narrowing.

Could Aldactone cause Intervertebral disc space narrowing?

Among these 12 people:

What is the gender of people who have Intervertebral disc space narrowing when taking Aldactone? *

female: 50 %
male: 50 %

What is the age of people who have Intervertebral disc space narrowing when taking Aldactone? *

What are other drugs people take besides Aldactone? *

What are other side effects people have besides Intervertebral disc space narrowing? *

Cardiac Failure Congestive: 11 people, 91.67%
Cellulitis (infection under the skin): 11 people, 91.67%
Osteonecrosis Of Jaw (death of bone of jaw): 11 people, 91.67%
Intervertebral Disc Protrusion (spinal disc protrusion): 11 people, 91.67%
Scoliosis (a medical condition in which a person's spine is curved from side to side): 10 people, 83.33%
Decreased Interest: 10 people, 83.33%
Pneumonia: 10 people, 83.33%
Neck Pain: 10 people, 83.33%
Pain: 10 people, 83.33%
Spinal Osteoarthritis (joint cartilage loss in spine): 10 people, 83.33%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 7 people, 58.33%
Bone Disorder: 6 people, 50.00%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 8.33%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 8.33%
Back Pain: 1 person, 8.33%
Breast Cancer Metastatic: 1 person, 8.33%
Constipation: 1 person, 8.33%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 8.33%
Faeces Hard: 1 person, 8.33%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Aldactone and have Intervertebral disc space narrowing?

- Check whether Intervertebral disc space narrowing is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aldactone:

Aldactone (46,063 reports)

Browse all side effects of Aldactone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (452 drugs)

Browse all the conditions that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (316 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on spironolactone (the active ingredients of Aldactone) and Aldactone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.